Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Investment Securities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Gains from Investment Securities for 4 consecutive years, with $65000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Gains from Investment Securities fell 26.14% year-over-year to $65000.0, compared with a TTM value of $65000.0 through Dec 2023, down 95.92%, and an annual FY2024 reading of $1.3 million, up 1903.08% over the prior year.
  • Gains from Investment Securities was $65000.0 for Q3 2023 at Terns Pharmaceuticals, up from -$6000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.5 million in Q4 2020 and bottomed at -$6000.0 in Q4 2022.
  • Average Gains from Investment Securities over 4 years is $810592.9, with a median of $164000.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities plummeted 93.64% in 2022, then dropped 26.14% in 2023.
  • Year by year, Gains from Investment Securities stood at $2.5 million in 2020, then crashed by 43.91% to $1.4 million in 2021, then plummeted by 100.43% to -$6000.0 in 2022, then skyrocketed by 1183.33% to $65000.0 in 2023.
  • Business Quant data shows Gains from Investment Securities for TERN at $65000.0 in Q3 2023, -$6000.0 in Q4 2022, and $88000.0 in Q3 2022.